Literature DB >> 31162731

Chronic pulmonary aspergillosis in a tertiary care centre in Spain: A retrospective, observational study.

Juan Aguilar-Company1,2, María Teresa Martín3, Lidia Goterris-Bonet3, Alex Martinez-Marti2, Júlia Sampol4, Elisa Roldán5, Benito Almirante1, Isabel Ruiz-Camps1.   

Abstract

The aim of this study was to describe the characteristics of patients with chronic pulmonary aspergillosis (CPA) in a tertiary care centre in Spain. Retrospective cohort study of all patients diagnosed with CPA between January 2010 and December 2015. The patients were identified through the Microbiology Registry. Demographic, clinical, laboratory, radiological, microbiological and clinical data were recorded. Patients were followed up for 12 months. Fifty-three patients were included; median age was 61.5 years. Forty-seven had a lung condition, 25 suffered from COPD, 19 an active malignancy, 10 had previous pulmonary tuberculosis and 9 lung interstitial disease. Twenty-eight patients presented with chronic cavitary pulmonary form (CCPA) and 20 with subacute invasive aspergillosis (SAIA). Species identified were A fumigatus (34), A niger (5), A terreus (4) and A flavus (3). All-cause 1-year mortality was 56%. Predictors of mortality were cancer history (OR, 9.5; 95% CI, 2.54-35.51; P < 0.01) and SAIA (OR, 5.49; 95% CI, 1.49-19.82; P < 0.01). Previous pulmonary tuberculosis, surgery for the treatment of CPA and CCPA were found to be associated with lower mortality (OR, 0.05; 95% CI, <0.01-0.47; P < 0.01; OR, 0.16; 95% CI, 0.03-0.88; P = 0.035 and OR 0.2, 95% CI, 0.01-0.67; P = 0.01, respectively). This is the first study providing an overview of the features of CPA in patients from Spain. CCPA was the most frequent form of CPA and A fumigatus the most frequently isolated species. Patients with cancer history and SAIA had a worse prognosis.
© 2019 Blackwell Verlag GmbH.

Entities:  

Keywords:  Aspergillus infection; Mycoses; chronic pulmonary aspergillosis; fungal lung disease; galactomannan; immunocompromised host; lung cancer

Mesh:

Year:  2019        PMID: 31162731     DOI: 10.1111/myc.12950

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  6 in total

Review 1.  Respiratory Mycoses in COPD and Bronchiectasis.

Authors:  Pei Yee Tiew; Micheál Mac Aogáin; Soo Kai Ter; Stefano Aliberti; James D Chalmers; Sanjay H Chotirmall
Journal:  Mycopathologia       Date:  2021-03-11       Impact factor: 2.574

2.  A Multidisciplinary Approach to Fungal Infections: One-Year Experiences of a Center of Expertise in Mycology.

Authors:  Nico A F Janssen; Roger J M Brüggemann; Monique H Reijers; Stefanie S V Henriet; Jaap Ten Oever; Quirijn de Mast; Yvonne Berk; Elizabeth A de Kort; Bart Jan Kullberg; Mihai G Netea; Jochem B Buil; Janette C Rahamat-Langendoen; Didi Bury; Eline W Muilwijk; Jacques F Meis; Paul E Verweij; Frank L van de Veerdonk
Journal:  J Fungi (Basel)       Date:  2020-11-10

3.  Prognostic factors of chronic pulmonary aspergillosis: A retrospective cohort of 264 patients from Japan.

Authors:  Yuya Kimura; Yuka Sasaki; Junko Suzuki; Jun Suzuki; Hiroshi Igei; Maho Suzukawa; Hirotoshi Matsui
Journal:  PLoS One       Date:  2021-04-01       Impact factor: 3.240

4.  Genetic and Phenotypic Characterization of in-Host Developed Azole-Resistant Aspergillus flavus Isolates.

Authors:  Jochem B Buil; Jos Houbraken; Monique H Reijers; Jan Zoll; Maurizio Sanguinetti; Jacques F Meis; Paul E Verweij; Willem J G Melchers
Journal:  J Fungi (Basel)       Date:  2021-02-25

5.  Chronic Pulmonary Aspergillosis: Burden, Clinical Characteristics and Treatment Outcomes at a Large Australian Tertiary Hospital.

Authors:  Olivier Despois; Sharon C-A Chen; Nicole Gilroy; Michael Jones; Peter Wu; Justin Beardsley
Journal:  J Fungi (Basel)       Date:  2022-01-25

6.  Prevalence of invasive aspergillosis in suspected pulmonary tuberculosis at a referral tuberculosis hospital in Shandong, China.

Authors:  Jun-Li Wang; Xiao-Lin Zhou; Chao Han; Mao-Shui Wang; Hua Hu
Journal:  Epidemiol Infect       Date:  2020-11-05       Impact factor: 2.451

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.